



the **Hydroponics** company

www.thcl.com.au

ASX RELEASE (12th January 2018)

Appointment of New Director

The Hydroponics Company Limited (ASX:THC) (“the **Company**”) reports the appointment of Mr Steven Xu effective this day as a Director of the Company.

Mr Xu is a director of Une-Innovation Consulting Australia Pty Ltd and Director of the MY INP Venture Capital Fund. Together Une-Innovation and the MY INP Venture Capital Fund hold 6.4% of the shares in the Company and are substantial shareholders.

Mr Xu is a Chartered Accountant (CA ANZ) and has 15 years’ experience working at PricewaterhouseCoopers and other listed companies in Australia and China. He specialises in financing, IPO and M&A activities in a broad range of sectors.

As head of the MY INP Venture Capital Mr Xu has experience with global investments in Medicinal Cannabis and related industry companies. He has strong international connections, especially in North America, Israel and China.

Mr Xu’s skills are an important addition to the Board’s collective skill set at this time given it’s plans to grow the current business.

The Board welcomes Mr Xu to the Company



The Hydroponics Company Limited
(ASX: THC) ACN: 614 508 039

Suite 305, Level 3
35 Lime Street
Sydney NSW 2000

For further information, please contact:



Jarrod White
Company Secretary | Chief Financial Officer
The Hydroponics Company Limited

Suite 305, Level 3, 35 Lime Street
Sydney NSW 2000

P: +61 2 9251 7177



Michael Lovesey
Director Corporate Media Relations
MMR Corporate Services Pty Ltd

Level 2, 131 Macquarie Street
Sydney, NSW 2000 Australia

P: +61 2 9251 7177

M: +61 449 607 636

E: michaell@mmlrcorporate.com

About The Hydroponics Company

The Hydroponics Company (ASX: THC) is at the forefront of developing a leading, diversified worldwide cannabis business, focused on three core business units: Development and delivery of medicinal cannabis, manufacturing and distribution of hydroponics equipment, materials and nutrients, and large scale hydroponic greenhouse design and construction. With +17 years of Cannabis sativa breeding, variety selection and growth management, THC is actively developing plant breeding technology to target multiple markets for high purity cannabidiol (CBD), a new class of medicinal product that can be used to target dementia, epilepsy and other neurological disorders.